GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vilin Bio Med Ltd (NSE:VILINBIO) » Definitions » Cash Flow from Financing

Vilin Bio Med (NSE:VILINBIO) Cash Flow from Financing : ₹125.93 Mil (TTM As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Vilin Bio Med Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Sep. 2023, Vilin Bio Med received ₹120.00 Mil more from issuing new shares than it paid to buy back shares. It received ₹5.93 Mil from issuing more debt. It paid ₹0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received ₹0.00 Mil from paying cash dividends to shareholders. It received ₹0.00 Mil on other financial activities. In all, Vilin Bio Med earned ₹125.93 Mil on financial activities for the six months ended in Sep. 2023.


Vilin Bio Med Cash Flow from Financing Historical Data

The historical data trend for Vilin Bio Med's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vilin Bio Med Cash Flow from Financing Chart

Vilin Bio Med Annual Data
Trend Mar20 Mar21 Mar22
Cash Flow from Financing
15.07 9.82 -2.16

Vilin Bio Med Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Sep23
Cash Flow from Financing - - - - 125.93

Vilin Bio Med Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Vilin Bio Med's Cash from Financing for the fiscal year that ended in Mar. 2022 is calculated as:

Vilin Bio Med's Cash from Financing for the quarter that ended in Sep. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹125.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vilin Bio Med  (NSE:VILINBIO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Vilin Bio Med's issuance of stock for the six months ended in Sep. 2023 was ₹120.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Vilin Bio Med's repurchase of stock for the six months ended in Sep. 2023 was ₹0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Vilin Bio Med's net issuance of debt for the six months ended in Sep. 2023 was ₹5.93 Mil. Vilin Bio Med received ₹5.93 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Vilin Bio Med's net issuance of preferred for the six months ended in Sep. 2023 was ₹0.00 Mil. Vilin Bio Med paid ₹0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Vilin Bio Med's cash flow for dividends for the six months ended in Sep. 2023 was ₹0.00 Mil. Vilin Bio Med received ₹0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Vilin Bio Med's other financing for the six months ended in Sep. 2023 was ₹0.00 Mil. Vilin Bio Med received ₹0.00 Mil on other financial activities.


Vilin Bio Med Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Vilin Bio Med's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Vilin Bio Med (NSE:VILINBIO) Business Description

Traded in Other Exchanges
N/A
Address
Opposite Sub Registrar’s Office, Survey No.115/GF/J, Hanumanji Colony, Bowempally, Secunderabad, TG, IND, 500009
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules & Nutritional Food supplements.

Vilin Bio Med (NSE:VILINBIO) Headlines

No Headlines